eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2022
vol. 17
 
Share:
Send email
Share:
abstract:
Review paper

Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data

Joaquim Prado P. Moraes-Filho
1
,
Gerson Domingues
2
,
Décio Chinzon
1
,
Juliana Leite Soares Guedes
3
,
Cláudia Yang Santos
3
,
Schlioma Zaterka
1

  1. Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, SP, Brazil
  2. Gastroenterology Department, Medical School, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  3. Takeda Pharmaceuticals, Brazil
Gastroenterology Rev 2022; 17 (4): 266–273
DOI: https://doi.org/10.5114/pg.2022.112777
Online publish date: 2022/01/23
View full text Get citation
 
PlumX metrics:
Introduction
Although potassium-competitive acid blockers (P-CABs) prompted safety concerns when first developed, they ultimately proved to have a favourable safety profile.

Aim
To assess the safety of vonoprazan in the management of gastroesophageal reflux disease (GERD), peptic ulcers, or gastroduodenal mucosal lesions induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).

Material and methods
From March to June 2021, a literature search was conducted using Medline via PubMed, Cochrane library, Lilacs, SciELO, and Centre for Reviews and Dissemination (CRD) electronic databases. After applying the eligibility criteria, 10 studies were included in this review. Of these 10 articles, vonoprazan was used as initial therapy in 6 and as maintenance therapy in 4. Adverse event rates were similar for vonoprazan and proton-pump inhibitors (PPIs).

Conclusions
Our findings suggest that vonoprazan is a safe option for the management of erosive oesophagitis, gastric/peptic ulcers, or peptic ulcers induced by chronic use of aspirin or NSAIDs.

keywords:

oesophagitis, systematic review, gastroesophageal reflux
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.